Publikacje:
Prace oryginalne: 120, prace poglądowe: 79, rozdziały w książkach: 39, komunikaty zjazdowe: 128
Wykaz 20 najważniejszych publikacji
1. Flisiak R., Li J., Baraona E., Lieber C.S.: Effects of ethanol on prostanoids production by liver fat-storing cells. Hepatology, 1993, 18, 153-159.
2. Flisiak R., Prokopowicz D.: Plasma iPGE2 and i6-keto prostaglandin F1 in the course of liver cirrhosis. Prostaglandins, 1997, 53, 1, 11-20.
3. Flisiak R., Prokopowicz D.: Effect of misoprostol on serum -microglobulin in the course of viral hepatitis B. Eur. J. Hepatol.-Gastroenterol., 1999, 11, 11, 1227-1230.
4. Flisiak R., Pytel-Krolczuk B., Prokopowicz D.: Circulating transforming growth factor as an indicator of hepatic function impairment in liver cirrhosis. Cytokine, 2000, 12, 6, 677-681
5. Flisiak R., Maxwell P., Prokopowicz D., Timms P.M., Panasiuk A.: Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor 1, possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepato-Gastroenterology, 2002, 49, 1369-1372.
6. Flisiak R., Al-Kadasi H., Jaroszewicz J., Prokopowicz D., Flisiak I.: Effect of lamivudine treatment on plasma levels of transforming growth factor 1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World J. Gastroenterol., 2004, 10(18): 2661-2665.
7. Lau G., Piratvisuth S., Luo K.X., Marcellin P., Thongasawat S., Cooksley G., Gane E., Fried M., Chow W.C., Paik S.W., Chang W.Y., Berg T., Flisiak R., Zahm F., Pluck N.: Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352(26): 2682-2695.
8. Flisiak R., Jaroszewicz J., Łapiński T.W., Flisiak I., Rogalska M., Prokopowicz D. Plasma transforming growth factor 1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B. Regulatory Peptides 2005; 131(1-3): 54-58.
9. Maxwell PR, Flisiak R. Evaluation of -Glutathione-S-transferase as a biomarker of lamivudine therapy for chronic hepatitis B. Dig Dis Sci 2006, 51 (10):1706-1711
10. Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HL. Peginterferon alpha-2b is safe and effective in HBeAg positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007, 46 (2): 288-294.
11. Flisiak R, Dumont J-M, Crabbe R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 2007; 16(9): 1345-1354.
12. Flisiak R, Horban A, Gallay P, Bobardt M, Selvarayah S, Wiercinska-Drapalo A, Siwak E, Cielniak I, Higersberger J, Kierkus J, Aeschlimann C, Grosgurin P, Nicolas-Métral V, Dumont J-M, Porchet H, Crabbé R, Scalfaro P. The cyclophilin inhibitor Debio-025 shows potent anti-HCV effect inpatients coinfected with hepatitis C and human immunodeficiency virus. Hepatology, 2008, 47, 3: 817-826.
13. Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, Flisiak R, Rehak V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48 (2): 407-417.
14. Marcellin P, Heathcote EJ, Buti M, Gane E, deMan RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. N Engl J Med 2008; 359:2442-2455.
15. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, Heathcote JE, Mazzella G, Vandelli C, Nicolas-Métral V, Grosgurin P, Liz JS, Scalfaro P, Porchet H, Crabbé R. The cyclophilin inhibitor Debio 025 combined with peg-IFN2a significantly reduces viral load in treatment naïve hepatitis C patients. Hepatology, 2009; 49(5): 1460-1468.
16. Flisiak R, Parfieniuk A. Investigational drugs for hepatitis C. Expert Opinion on Invest Drugs, 2010; 19(1): 63-75.
17. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee C-M, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG. Randomized Trial of albinterferon alfa-2b for the Treatment of Patients With Chronic Hepatitis C Virus Genotype 2 or 3. Gastroenterology 2010; 139(4):1267-76.
18. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CAB, ter Borg MJ, Janssen HLA. Early prediction of sustained response to peginterferon alfa-2a in HBeAg-negative patients: The role of on-treatment HBsAg and HBV DNA levels. Hepatology, 2010; 52(2): 454-461.
19. Flisiak R, Flisiak I. Albinterferon-alfa 2b: a new treatment option for hepatitis C. Expert Opin Biol Ther 2010; 10(10): 1509-15.
20. Heathcote EJ, Marcellin P, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G,Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F,Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. Gastroenterology 2011; 140: 132-143
Podziękowania dla lekarza
Podziękuj lekarzowi i poleć go innym!
Jeżeli lekarz pomógł Ci wrócić do zdrowia, warto wpisać słowa podziękowania lub pozytywną opinię, aby polecić go w ten sposób innym pacjentom.
Formularz nie służy do kontaktu z lekarzem i rejestracji na wizyty.
Uwaga: po zaakceptowaniu przez moderatora, treść Twoich podziękowań będzie widoczna publicznie w profilu lekarza.